JP2017508737A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508737A5
JP2017508737A5 JP2016552579A JP2016552579A JP2017508737A5 JP 2017508737 A5 JP2017508737 A5 JP 2017508737A5 JP 2016552579 A JP2016552579 A JP 2016552579A JP 2016552579 A JP2016552579 A JP 2016552579A JP 2017508737 A5 JP2017508737 A5 JP 2017508737A5
Authority
JP
Japan
Prior art keywords
mcg
csf
days
analog
retinoid agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508737A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/016447 external-priority patent/WO2015126989A1/en
Publication of JP2017508737A publication Critical patent/JP2017508737A/ja
Publication of JP2017508737A5 publication Critical patent/JP2017508737A5/ja
Pending legal-status Critical Current

Links

JP2016552579A 2014-02-18 2015-02-18 好中球減少症の治療用の組成物及び方法 Pending JP2017508737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461941233P 2014-02-18 2014-02-18
US61/941,233 2014-02-18
PCT/US2015/016447 WO2015126989A1 (en) 2014-02-18 2015-02-18 Compositions and methods for treating neutropenia

Publications (2)

Publication Number Publication Date
JP2017508737A JP2017508737A (ja) 2017-03-30
JP2017508737A5 true JP2017508737A5 (enExample) 2018-03-29

Family

ID=53878925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552579A Pending JP2017508737A (ja) 2014-02-18 2015-02-18 好中球減少症の治療用の組成物及び方法

Country Status (11)

Country Link
US (1) US10286039B2 (enExample)
EP (1) EP3107533A4 (enExample)
JP (1) JP2017508737A (enExample)
KR (1) KR20160113302A (enExample)
CN (1) CN106413701A (enExample)
AU (1) AU2015219038B2 (enExample)
CA (1) CA2937340C (enExample)
MX (1) MX2016010699A (enExample)
RU (1) RU2016136833A (enExample)
WO (1) WO2015126989A1 (enExample)
ZA (1) ZA201605109B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
CN107130026B (zh) * 2017-05-15 2018-03-09 新疆医科大学第四附属医院 一种结直肠癌诊断和治疗效果评价相关的基因
CN111886008B (zh) * 2017-10-18 2024-05-31 港大科桥有限公司 用于抗mers-冠状病毒治疗的组合物和方法
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
ZA9711342B (en) 1996-12-19 1999-06-17 American Cyanamid Co Method of treating or inhibiting neutropenia
AU2001290846B2 (en) 2000-09-08 2006-02-02 Massachusetts Institute Of Technology G-CSF analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003902308A0 (en) 2003-05-14 2003-05-29 Diagnose It Pty Ltd A method and system for the monitoring of medical conditions
JPWO2004100972A1 (ja) 2003-05-16 2006-07-13 協和醗酵工業株式会社 組織破壊を伴う疾患の予防及び/または治療剤
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
EP1796716A4 (en) 2004-08-13 2010-09-08 Anormed Inc COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
DE602005022939D1 (de) 2004-12-02 2010-09-23 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta-lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
US20090111786A1 (en) 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
CA2681712C (en) 2007-03-30 2013-05-07 Tmrc Co., Ltd. Tamibarotene capsule preparation
EP2231187A4 (en) 2007-12-06 2013-02-20 Csl Ltd PROCESS FOR SUPPRESSING LEUKEMIA STEM CELLS
EP2334814A4 (en) * 2008-09-05 2012-04-25 Solulink Biosciences Inc METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA INJURIES
JP2013508352A (ja) * 2009-10-19 2013-03-07 ライラ ニュートラシューティカルズ アセトゲニンを含む抽出物、フラクションおよび組成物ならびにそれらの応用
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) * 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
CN105684283A (zh) 2013-07-04 2016-06-15 利纳克有限公司 致动器系统
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Similar Documents

Publication Publication Date Title
JP2021527092A5 (enExample)
JP2019503365A5 (enExample)
JP2013533858A5 (enExample)
CN101636145A (zh) 长期24小时经肠给予左旋多巴/卡比多巴
JP2014528474A5 (enExample)
JP2018520189A5 (enExample)
JP2011190199A (ja) 関節リウマチ薬
IL292770A (en) Formulations and dosages of polyethylene glycol-modified oricase
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
RU2016136833A (ru) Композиции и способы для лечения нейтропении
JP2016505050A5 (enExample)
CN1913902A (zh) 使用喹硫平抗精神病药物治疗精神疾病
JP2023502053A5 (enExample)
JP2023531930A5 (enExample)
CN1287855C (zh) B型慢性肝炎治疗剂
JP2022526643A5 (enExample)
US8198293B2 (en) Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases
JP2022518527A5 (enExample)
JP2021091608A5 (enExample)
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
JP2015520759A5 (enExample)
JP2025521501A5 (enExample)
RU2013155476A (ru) Композиции и способы изменения фенотипов xlhed
EP2307018B1 (en) Oxymatrine compositions and use thereof for treating and preventing chronic infectious diseases